Allene Fonseca, in Dearborn, MI - Student in an Organized Health Care Education/Training Program

Allene Fonseca, is a Student In An Organized Health Care Education/training Program physician based in Dearborn, Michigan. Allene Fonseca is licensed to practice in Michigan (license number ) and her current practice location is 18100 Oakwood Blvd Ste 300, Dearborn, Michigan. She can be reached at her office (for appointments etc.) via phone at (313) 240-4900.

NPI number for Allene Fonseca is 1487008025 and her current mailing address is 18100 Oakwood Blvd Ste 300, Dearborn, Michigan. She does not participate in medicare program and thus does not accept medicare assignments. Her NPI Number is 1487008025.

Contact Information

	Allene Fonseca,
	18100 Oakwood Blvd Ste 300, Dearborn, MI 48124-4085
	(313) 240-4900
	(313) 429-7992

Physician's Profile

Full Name	Allene Fonseca
Gender	Female
Speciality	Student In An Organized Health Care Education/training Program
Location	18100 Oakwood Blvd Ste 300, Dearborn, Michigan
Accepts Medicare Assignments	Does not participate in Medicare Program. She may not accept medicare assignment.

NPI Data:

NPI Number: 1487008025
Provider Enumeration Date: 04/20/2016
Last Update Date: 06/30/2022

Medical Identifiers

Medical identifiers for Allene Fonseca such as npi, medicare ID, medicare PIN, medicaid, etc.

Identifier	Type	State	Issuer
1487008025	NPI	-	NPPES

Medical Taxonomies and Licenses

Taxonomy	Type	License (State)	Status
207N00000X	Dermatology	4351050138 (Michigan)	Secondary
207R00000X	Internal Medicine	A150457 (California)	Secondary
390200000X	Student In An Organized Health Care Education/training Program	(Michigan)	Primary

Medicare Part D Prescriber Enrollment

Any physician or other eligible professional who prescribes Part D drugs must either enroll in the Medicare program or opt out in order to prescribe drugs to their patients with Part D prescription drug benefit plans. Allene Fonseca is NOT enrolled with medicare and thus cannot prescribe medicare part D drugs to patients with medicare part D benefits.

Mailing Address and Practice Location

Mailing Address	Practice Location Address
Allene Fonseca, 18100 Oakwood Blvd Ste 300, Dearborn, MI 48124-4085 Ph: (313) 240-4900	Allene Fonseca, 18100 Oakwood Blvd Ste 300, Dearborn, MI 48124-4085 Ph: (313) 240-4900

News Archive

New research shows link between perinatal exposure to BPA and risk of food intolerance in later life

If it seems like more people are allergic to, or intolerant of, more and different kinds of foods than ever before, there might be a reason why. A new research published in November 2014 issue of The FASEB Journal, scientists show, for the first time, that there is a link between perinatal exposure to Bisphenol A (BPA) at low doses and the risk to develop food intolerance in later life.

Medical or surgical treatment for severe heartburn prevents esophageal cancer

Medical or surgical treatment of severe heartburn prevents cancer of the esophagus, a study from Karolinska Institutet with almost one million Nordic patients reveals. The results will be published in the scientific journal JAMA Oncology.

Pharmasset initiates dosing in PSI-7977 exploratory study in HCV

Pharmasset, Inc. announced today that dosing has begun in an exploratory study of PSI-7977, a nucleotide analog polymerase inhibitor, for the treatment of chronic hepatitis C (HCV). The trial will evaluate PSI-7977 400mg QD in combination with ribavirin (RBV), with 0, 4, 8, or 12 weeks of pegylated interferon alfa 2a (Peg-IFN) in treatment-naive patients infected with HCV genotype 2 or 3.

FDA approves Jevtana to treat men with prostate cancer

The U.S. Food and Drug Administration today approved Jevtana (cabazitaxel), a chemotherapy drug used in combination with the steroid prednisone to treat men with prostate cancer. Jevtana is the first treatment for advanced, hormone-refractory, prostate cancer that has worsened during or after treatment with docetaxel, a commonly used drug for advanced prostate cancer.

Next-generation nanomedicine

In an article featured on the cover of the March issue of Nature Nanotechnology, Mauro Ferrari, Ph.D., of The University of Texas Health Science Center at Houston, presented a proof-of-concept study on a new multistage delivery system (MDS) for imaging and therapeutic applications. This discovery could go a long way toward making injectable drugs more effective.

Allene Fonseca, - Student in an Organized Health Care Education/Training Program in Dearborn, MI